Serum Hypoxia-Inducible Factor 1alpha Levels Correlate with Outcomes After Intracerebral Hemorrhage.

hypoxia-inducible factor 1alpha intracerebral hemorrhage prognosis severity

Journal

Therapeutics and clinical risk management
ISSN: 1176-6336
Titre abrégé: Ther Clin Risk Manag
Pays: New Zealand
ID NLM: 101253281

Informations de publication

Date de publication:
2021
Historique:
received: 07 04 2021
accepted: 25 06 2021
entrez: 21 7 2021
pubmed: 22 7 2021
medline: 22 7 2021
Statut: epublish

Résumé

Serum hypoxia-inducible factor 1alpha (HIF-1α) is a key regulator in hypoxic and ischemic brain injury. We determined the relationship between serum HIF-1α levels and long-term prognosis plus severity of intracerebral hemorrhage (ICH). A total of 97 ICH cases and 97 healthy controls were enrolled. Glasgow Coma Scale (GCS) score and hematoma volume were used to assess hemorrhagic severity. Glasgow Outcome Scale (GOS) score of 1-3 at post-stroke 90 days was defined as a poor outcome. Serum HIF-1α levels of ICH patients were significantly higher than those of healthy controls (median, 218.8 vs 105.4 pg/mL; P<0.001) and were substantially correlated with GCS score ( Serum HIF-1α, in close correlation with hemorrhagic severity and poor 90-day outcome, may serve as a potential prognostic biomarker for ICH.

Sections du résumé

BACKGROUND BACKGROUND
Serum hypoxia-inducible factor 1alpha (HIF-1α) is a key regulator in hypoxic and ischemic brain injury. We determined the relationship between serum HIF-1α levels and long-term prognosis plus severity of intracerebral hemorrhage (ICH).
METHODS METHODS
A total of 97 ICH cases and 97 healthy controls were enrolled. Glasgow Coma Scale (GCS) score and hematoma volume were used to assess hemorrhagic severity. Glasgow Outcome Scale (GOS) score of 1-3 at post-stroke 90 days was defined as a poor outcome.
RESULTS RESULTS
Serum HIF-1α levels of ICH patients were significantly higher than those of healthy controls (median, 218.8 vs 105.4 pg/mL; P<0.001) and were substantially correlated with GCS score (
CONCLUSION CONCLUSIONS
Serum HIF-1α, in close correlation with hemorrhagic severity and poor 90-day outcome, may serve as a potential prognostic biomarker for ICH.

Identifiants

pubmed: 34285494
doi: 10.2147/TCRM.S313433
pii: 313433
pmc: PMC8286156
doi:

Types de publication

Journal Article

Langues

eng

Pagination

717-726

Informations de copyright

© 2021 Cai et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

J Neurosurg. 1987 Apr;66(4):555-62
pubmed: 3559721
J Neurosurg. 1986 Nov;65(5):697-703
pubmed: 3772459
Acta Neuropathol Commun. 2014 May 05;2:51
pubmed: 24887017
J Biol Chem. 2000 Sep 1;275(35):26765-71
pubmed: 10837481
J Mol Neurosci. 2012 Sep;48(1):273-80
pubmed: 22528459
Neuroreport. 2014 Oct 1;25(14):1122-8
pubmed: 25089804
J Neurosurg. 1995 Dec;83(6):1045-50
pubmed: 7490619
Curr Med Chem. 2009;16(34):4593-600
pubmed: 19903149
J Cereb Blood Flow Metab. 2002 Jun;22(6):689-96
pubmed: 12045667
Cerebrovasc Dis. 2014;38(6):395-409
pubmed: 25471997
J Neurosci. 2007 Jun 6;27(23):6320-32
pubmed: 17554006
Ann Neurol. 2000 Sep;48(3):285-96
pubmed: 10976634
Mol Pharmacol. 2006 Nov;70(5):1469-80
pubmed: 16887934
Eur J Neurosci. 1999 Dec;11(12):4159-70
pubmed: 10594641
J Neurol Sci. 2017 Apr 15;375:52-57
pubmed: 28320188
J Neurosci. 1999 Aug 15;19(16):6818-24
pubmed: 10436039
Neurosci Lett. 2009 Mar 27;453(1):68-72
pubmed: 19429018
Pharm Biol. 2020 Dec;58(1):438-446
pubmed: 32432963
J Clin Invest. 2000 Oct;106(7):809-12
pubmed: 11018065
Curr Neurovasc Res. 2011 Feb;8(1):44-51
pubmed: 21208160
Neurosci Lett. 1998 Sep 25;254(2):117-20
pubmed: 9779934
Am J Transl Res. 2017 Mar 15;9(3):1521-1529
pubmed: 28386377
J Neuropathol Exp Neurol. 2014 Oct;73(10):975-86
pubmed: 25192050
Brain Res. 1999 May 22;829(1-2):125-33
pubmed: 10350538
Neurochem Res. 2019 Jan;44(1):258-268
pubmed: 29589179
Stroke. 1996 Aug;27(8):1304-5
pubmed: 8711791
EMBO J. 1998 Nov 16;17(22):6573-86
pubmed: 9822602
J Neurosci. 2005 Apr 20;25(16):4099-107
pubmed: 15843612
Oncogene. 2010 Feb 4;29(5):625-34
pubmed: 19946328
Nature. 1998 Jul 30;394(6692):485-90
pubmed: 9697772
Cancer Sci. 2018 Mar;109(3):560-571
pubmed: 29285833
Semin Neurol. 2010 Nov;30(5):555-64
pubmed: 21207348

Auteurs

Yong Cai (Y)

The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang Province, People's Republic of China.

Yao-Kun Zhuang (YK)

The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang Province, People's Republic of China.

Xiao-Yu Wu (XY)

The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang Province, People's Republic of China.

Xiao-Qiao Dong (XQ)

Department of Neurosurgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang Province, People's Republic of China.

Quan Du (Q)

Department of Neurosurgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang Province, People's Republic of China.

Wen-Hua Yu (WH)

Department of Neurosurgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang Province, People's Republic of China.

Ke-Yi Wang (KY)

Department of Neurosurgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang Province, People's Republic of China.

Wei Hu (W)

Department of Intensive Care Unit, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang Province, People's Republic of China.

Yong-Ke Zheng (YK)

Department of Intensive Care Unit, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang Province, People's Republic of China.

Classifications MeSH